Korman, Max J <br/><br/>
Are PCSK9 Inhibitors Cost Effective?  [electronic resource] 

 -  PharmacoEconomics  09 2018 
 - 1031-1041 p.  digital 
<br/><br/> Publication Type: Journal Article; Review 
<br/><br/><label>ISSN: </label>1179-2027 
<br/><br/><label>Standard No.: </label>10.1007/s40273-018-0671-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anticholesteremic Agents--economics<br/>Cost-Benefit Analysis--statistics & numerical data<br/>Drug Therapy, Combination--economics<br/>Enzyme Inhibitors--economics<br/>Ezetimibe--economics<br/>Humans<br/>Hydroxymethylglutaryl-CoA Reductase Inhibitors--economics<br/>Hypercholesterolemia--drug therapy<br/>PCSK9 Inhibitors<br/>Quality-Adjusted Life Years